Sybil Akua Okyerewa Obuobi

Sybil-1
Foto: Christian Halvorsen, UiT

Sybil Akua Okyerewa Obuobi

COALITION: BaCteria respOnsive And intrinsicaLly actIve anTimIcrObial Nanohybrids

VERTSINSTITUTT: Department of Pharmacy, Health faculty
PERIODE: 2021-2025
BEVILGNING: 12 MNOK
HJEMMESIDE

On wound surfaces, bacteria can form large numbers of slimy glue-like membranes that stick on the wound and slow down the healing process. These slimy communities of bacteria, termed biofilms, account for at least two-thirds of all clinical infections and are especially difficult to treat. Because many antimicrobials used in clinical practice have poor biofilm penetration, biofilms are up to 1000 times more resistant to antibiotics. Consequently, more than two-thirds of antibiotics are ineffective. This enhances the risk of developing resistant infections. There is therefore an urgent need to improve biofilm penetration and enhance the activity of antimicrobials.

The main goal of this TFS project is to generate non-toxic antimicrobials with improved activity against biofilms and faster wound healing as innovative medicines for the treatment of biofilm wound infections. The results of this study will also aid the development of new tools to combat antimicrobial resistance.

Dr. Sybil Obuobi obtained her bachelors in Pharmacy at the Kwame Nkrumah University of Science and Technology (Ghana) and studied Drug delivery at Aston University (UK) before joining the National University of Singapore (Singapore) for her PhD. In 2019, she received a Marie Curie Fellowship to join the Department of Pharmacy (Drug Transport and Delivery Research Group) at UIT The Arctic University of Norway as an independent researcher where she focused on developing antimicrobial hybrids for the treatment of persistent infections. This TFS project will be conducted within the same department in collaboration with international collaborators from Denmark and Finland.